Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00025477.xml
Download PDF
CC BY 4.0 · Int Arch Otorhinolaryngol 2025; 29(03): s00451809645
DOI: 10.1055/s-0045-1809645
DOI: 10.1055/s-0045-1809645
Original Research
Melatonin Prevents Cisplatin-Induced Cyto-Histopathological Damage in the Bone Marrow and Inner Ear
Funding The authors declare that they did not receive funding from agencies in the public, private, or non-profit sectors to conduct the present study.
Abstract
Introduction
Cisplatin is an effective chemotherapeutic drug. Its side effects, ototoxicity and genotoxicity, limit widespread application. Melatonin could reduce these toxic effects due to its antioxidant activity.
Objective
To determine the effect of melatonin against cisplatin-induced ototoxicity and genotoxicity in rats.
Methods
To assess ototoxicity, 33 rats were randomly divided into: group 1 (saline), group 2 (melatonin), group 3 (cisplatin + saline), and group 4 (cisplatin + melatonin). Groups 3 and 4 received a single dose of 10 mg/kg of cisplatin. Groups 2 and 4 received daily doses of 1 mg/kg of melatonin. The number of viable neurons and their average diameter in the spiral and vestibular ganglia were analyzed. In the stria vascularis and spiral ligament, the number of viable cells was evaluated. To assess genotoxicity, 12 animals were randomly divided into: group A (saline), group B (cisplatin + saline), and group C (cisplatin + melatonin). The rats in groups B and C received a single dose of 10 mg/kg of cisplatin. Group C received a single dose of 1 mg/kg of melatonin.
Results
The micronucleus count and percentage of polychromatic erythrocytes in the bone marrow of rat femurs were analyzed. The animals in group 3 presented a greater loss of cells than the animals in other groups regarding all cochlear structures evaluated. Furthermore, the diameters of neurons were smaller in the animals in group 3. Melatonin-treated rats presented a lower micronucleus count and a higher number of polychromatic erythrocytes than animals treated with cisplatin alone.
Conclusion
Melatonin reduces cisplatin-induced cyto-histopathological damage in the bone marrow and inner ear; therefore, it could be used as a tumor adjuvant treatment.
Note
The data that support the findings of the present study are available from the corresponding author upon reasonable request.
Publication History
Received: 22 November 2024
Accepted: 24 March 2025
Article published online:
10 September 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Bibliographical Record
Juliana Gusmão de Araujo, Lucieny Silva Martins Serra, Lucas Lauand, Selma Aparecida Souza Kückelhaus, André Luiz Lopes Sampaio. Melatonin Prevents Cisplatin-Induced Cyto-Histopathological Damage in the Bone Marrow and Inner Ear. Int Arch Otorhinolaryngol 2025; 29: s00451809645.
DOI: 10.1055/s-0045-1809645
Juliana Gusmão de Araujo, Lucieny Silva Martins Serra, Lucas Lauand, Selma Aparecida Souza Kückelhaus, André Luiz Lopes Sampaio. Melatonin Prevents Cisplatin-Induced Cyto-Histopathological Damage in the Bone Marrow and Inner Ear. Int Arch Otorhinolaryngol 2025; 29: s00451809645.
DOI: 10.1055/s-0045-1809645
-
References
- 1 Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB. Platinum antitumor complexes: 50 Years since Barnett Rosenberg's discovery. J Clin Oncol 2015; 33 (35) 4219-4226
- 2 Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel M-T. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 2008; 15 (26) 2656-2663
- 3 Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57 (8-9): 1229-1235
- 4 Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982; 66 (01) 19-23
- 5 Landier W. Ototoxicity and cancer therapy. Cancer 2016; 122 (11) 1647-1658
- 6 Sergi B, Ferraresi A, Troiani D, Paludetti G, Fetoni AR. Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res 2003; 182 (1-2): 56-64
- 7 Sockalingam R, Freeman S, Cherny TL, Sohmer H. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol 2000; 21 (04) 521-527
- 8 Cardinaal RM, De Groot JCMJ, Huizing EH, Veldman JE, Smoorenburg GF. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res 2000; 144 (1-2): 135-146
- 9 Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007; 15 (05) 364-369
- 10 Theunissen EAR, Dreschler WA, Latenstein MN, Rasch CRN, Van Der Baan S, De Boer JP. et al. A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol 2014; 123 (10) 711-718
- 11 Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40 (16) 2445-2451
- 12 Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos-Hernández F, Peñarroja-Flores R, Toledo-García J, Bravo JL. et al. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer. Mutat Res 2008; 640 (1-2): 8-15
- 13 Bubley GJ, Teicher BA, Ogata GK, Sandoval LS, Kusumoto T. Differences in in vivo and in vitro sequence-specific sites of cisplatin-DNA adduct formation and detection of a dose-response relationship. Biochem Pharmacol 1994; 48 (01) 145-153
- 14 Szikriszt B, Póti Á, Pipek O, Krzystanek M, Kanu N, Molnár J. et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol 2016; 17 (99)
- 15 Choi DK, Helenowski I, Hijiya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer 2014; 135 (08) 1764-1773
- 16 Bilgic Y, Akbulut S, Aksungur Z, Erdemli ME, Ozhan O, Parlakpinar H. et al. Protective effect of dexpanthenol against cisplatin-induced hepatotoxicity. Exp Ther Med 2018; 16 (05) 4049-4057
- 17 Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004; 279 (19) 19948-19954
- 18 Sletten TL, Vincenzi S, Redman JR, Lockley SW, Rajaratnam SMW. Timing of sleep and its relationship with the endogenous melatonin rhythm. Front Neurol 2010; 1: 137
- 19 Urata Y, Honma S, Goto S, Todoroki S, Iida T, Cho S. et al. Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27 (7-8): 838-847
- 20 Erdemli ME, Zayman E, Erdemli Z, Gul M, Gul S, Gozukara Bag H. Protective effects of melatonin and vitamin E in acetamiprid-induced nephrotoxicity. Environ Sci Pollut Res Int 2020; 27 (09) 9202-9213
- 21 Araujo JGd, Serra LSM, Lauand L, Kückelhaus SAS, Sampaio ALL. Protective effect of melatonin on cisplatin-induced ototoxicity in rats. Anticancer Res 2019; 39 (05) 2453-2458
- 22 Tokgöz SA, Vuralkan E, Sonbay ND, Çalişkan M, Saka C, Beşalti Ö, Akin İ. Protective effects of vitamins E, B and C and L-carnitine in the prevention of cisplatin-induced ototoxicity in rats. J Laryngol Rhinol Otol 2012; 126 (05) 464-469
- 23 Yazici ZM, Meric A, Midi A, Arınc YV, Kahya V, Hafız G. Reduction of cisplatin ototoxicity in rats by oral administration of pomegranate extract. Eur Arch Otorhinolaryngol 2012; 269 (01) 45-52
- 24 Kaya H, Delibas N, Serteser M, Ulukaya E, Ozkaya O. The effect of melatonin on lipid peroxidation during radiotherapy in female rats. Strahlenther Onkol 1999; 175 (06) 285-288
- 25 Vijayalaxmi X, Meltz ML, Reiter RJ, Herman TS, Kumar KS. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat Res 1999; 425 (01) 21-27
- 26 Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50 (02) 271-279
- 27 Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M. et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999; 35 (12) 1688-1692
- 28 Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003; 35 (01) 12-15
- 29 Casado-Zapico S, Rodriguez-Blanco J, García-Santos G, Martín V, Sánchez-Sánchez AM, Antolín I, Rodriguez C. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res 2010; 48 (01) 72-80
- 30 Kubatka P, Zubor P, Busselberg D, Kwon TK, Adamek M, Petrovic D. et al. Melatonin and breast cancer: Evidences from preclinical and human studies. Crit Rev Oncol Hematol 2018; 122: 133-143
- 31 Gonzalez A, Castillo-Vaquero Ad, Miro-Moran A, Tapia JA, Salido GM. Melatonin reduces pancreatic tumor cell viability by altering mitochondrial physiology. J Pineal Res 2011; 50 (03) 250-260
- 32 Sookprasert A, Johns NP, Phunmanee A, Pongthai P, Cheawchanwattana A, Johns J. et al. Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial. Anticancer Res 2014; 34 (12) 7327-7337
- 33 Wang J, Hao H, Yao L, Zhang X, Zhao S, Ling E-A. et al. Melatonin suppresses migration and invasion via inhibition of oxidative stress pathway in glioma cells. J Pineal Res 2012; 53 (02) 180-187
- 34 Martín V, Herrera F, Carrera-Gonzalez P, García-Santos G, Antolín I, Rodriguez-Blanco J, Rodriguez C. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006; 66 (02) 1081-1088
- 35 García-Santos G, Antolín I, Herrera F, Martín V, Rodriguez-Blanco J, Carrera MdP, Rodriguez C. Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 2006; 41 (02) 130-135
- 36 Trubiani O, Recchioni R, Moroni F, Pizzicannella J, Caputi S, Di Primio R. Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation. J Pineal Res 2005; 39 (04) 425-431
- 37 Rubio S, Estévez F, Cabrera J, Reiter RJ, Loro J, Quintana J. Inhibition of proliferation and induction of apoptosis by melatonin in human myeloid HL-60 cells. J Pineal Res 2007; 42 (02) 131-138
- 38 Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S. et al. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Oncol Rep 1995; 2 (05) 871-873
- 39 Wang YM, Jin BZ, Ai F, Duan C-H, Lu Y-Z, Dong T-F, Fu Q-L. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol 2012; 69 (05) 1213-1220
- 40 Hara M, Yoshida M, Nishijima H, Yokosuka M, Iigo M, Ohtani-Kaneko R. et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001; 30 (03) 129-138
- 41 Parlakpinar H, Sahna E, Ozer MK, Ozugurlu F, Vardi N, Acet A. Physiological and pharmacological concentrations of melatonin protect against cisplatin-induced acute renal injury. J Pineal Res 2002; 33 (03) 161-166
- 42 Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226 (1-2): 157-167
- 43 Ye L-F, Tao ZZ, Hua QQ, Xiao B-K, Zhou X-H, Li J, Yuan Y-L. Protective effect of melatonin against gentamicin ototoxicity. J Laryngol Rhinol Otol 2009; 123 (06) 598-602
- 44 Lopez-Gonzalez MA, Guerrero JM, Torronteras R, Osuna C, Delgado F. Ototoxicity caused by aminoglycosides is ameliorated by melatonin without interfering with the antibiotic capacity of the drugs. J Pineal Res 2000; 28 (01) 26-33
- 45 Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995; 76 (06) 386-394
- 46 Freitas MR, Silva VC, Brito GA, Carvalho Junior JV, Gomes Junior RM, Ribeiro RdA. Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats. Braz J Otorhinolaryngol 2009; 75 (04) 476-484
- 47 Franceschi CM, Tochetto T, Silveira AF, Fantinel MR, Algarve TD. Cisplatin effects on guinea pigs: cochlear histology and genotoxicity. Braz J Otorhinolaryngol 2011; 77 (06) 728-735 10.1590/S1808-86942011000600009
- 48 Meech RP, Campbell KCM, Hughes LP, Rybak LP. A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res 1998; 124 (1-2): 44-59
- 49 Van Ruijven MWM, De Groot JCMJ, Klis SFL, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 2005; 205 (1-2): 241-248
- 50 Schaefer SD, Wright CG, Post JD, Frenkel EP. Cis-platinum vestibular toxicity. Cancer 1981; 47 (05) 857-859
- 51 Myers SF, Blakley BW, Schwan S. Is cis-platinum vestibulotoxic?. Otolaryngol Head Neck Surg 1993; 108 (04) 322-328
- 52 Dertinger SD, Avlasevich SL, Torous DK, Bemis JC, Phonethepswath S, Labash C. et al. Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy. Toxicol Sci 2014; 140 (02) 307-314
- 53 Rjiba-Touati K, Ayed-Boussema I, Skhiri H, Belarbia A, Zellema D, Achour A, Bacha H. Induction of DNA fragmentation, chromosome aberrations and micronuclei by cisplatin in rat bone-marrow cells: protective effect of recombinant human erythropoietin. Mutat Res 2012; 747 (02) 202-206